| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Viorica Ionut, Idit F Liberty, Katrin Hucking, Maya Lottati, Darko Stefanovski, Dan Zheng, Richard N Bergma. Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. American journal of physiology. Endocrinology and metabolism. vol 291. issue 4. 2006-10-24. PMID:16720628. |
however, infusion of glucose alone, without glp-1, produced a similar insulin response (37 +/- 6 to 82 +/- 14 pmol, 53% of the meal insulin, p = 0.7 vs. glucose and glp-1 infusion). |
2006-10-24 |
2023-08-12 |
dog |
| Rhonda D Wideman, Irene L Y Yu, Travis D Webber, C Bruce Verchere, James D Johnson, Anthony T Cheung, Timothy J Kieffe. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proceedings of the National Academy of Sciences of the United States of America. vol 103. issue 36. 2006-10-19. PMID:16938896. |
glucagon-like peptide 1 (glp-1) is a hormone that has received significant attention as a therapy for diabetes because of its ability to stimulate insulin biosynthesis and release and to promote growth and survival of insulin-producing beta cells. |
2006-10-19 |
2023-08-12 |
mouse |
| Rhonda D Wideman, Irene L Y Yu, Travis D Webber, C Bruce Verchere, James D Johnson, Anthony T Cheung, Timothy J Kieffe. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proceedings of the National Academy of Sciences of the United States of America. vol 103. issue 36. 2006-10-19. PMID:16938896. |
here, we show that adenovirus-mediated expression of pc1/3 in alpha cells increases islet glp-1 secretion, resulting in improved glucose-stimulated insulin secretion and enhanced survival in response to cytokine treatment. |
2006-10-19 |
2023-08-12 |
mouse |
| Klaus-Peter Knoch, Ronny Meisterfeld, Stephan Kersting, Hendrik Bergert, Anke Altkrüger, Carolin Wegbrod, Melanie Jäger, Hans-Detlev Saeger, Michele Solimen. cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in beta cells. Cell metabolism. vol 3. issue 2. 2006-10-06. PMID:16459313. |
glucagon-like peptide 1 (glp-1) potentiates glucose-stimulated insulin gene expression and secretion by increasing camp levels in beta cells. |
2006-10-06 |
2023-08-12 |
Not clear |
| George S Jeha, Rubina A Heptull. Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations. Pediatric diabetes. vol 7. issue 2. 2006-09-28. PMID:16629719. |
glucagon-like peptide-1 (glp-1) or agents that bind to its receptor (exenatide, byetta) or agents that inhibit its destruction [dipeptidyl peptidase-iv (dpp-iv) inhibitors, vildagliptin] improve insulin secretion, delay gastric emptying, and suppress glucagon secretion while decreasing food intake without increasing hypoglycemia. |
2006-09-28 |
2023-08-12 |
Not clear |
| Nicolai M Doliba, Wei Qin, Marko Z Vatamaniuk, Carol W Buettger, Heather W Collins, Mark A Magnuson, Klaus H Kaestner, David F Wilson, Richard D Carr, Franz M Matschinsk. Cholinergic regulation of fuel-induced hormone secretion and respiration of SUR1-/- mouse islets. American journal of physiology. Endocrinology and metabolism. vol 291. issue 3. 2006-09-26. PMID:16638820. |
neural and endocrine factors (i.e., ach and glp-1) restore defective glucose-stimulated insulin release in pancreatic islets lacking sulfonylurea type 1 receptors (sur1(-/-)) (doliba nm, qin w, vatamaniuk mz, li c, zelent d, najafi h, buettger cw, collins hw, carr rd, magnuson ma, and matschinsky fm. |
2006-09-26 |
2023-08-12 |
mouse |
| Tanya J Little, Selena Doran, James H Meyer, Andre J P M Smout, Deirdre G O'Donovan, Keng-Liang Wu, Karen L Jones, Judith Wishart, Christopher K Rayner, Michael Horowitz, Christine Feinle-Bisse. The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed. American journal of physiology. Endocrinology and metabolism. vol 291. issue 3. 2006-09-26. PMID:16684852. |
the aims of this study were to determine the effects of modifying the length of small intestine exposed to glucose on plasma concentrations of glp-1 and also glucose-dependent insulinotropic peptide (gip), insulin, cholecystokinin (cck) and ghrelin, and antropyloric pressures. |
2006-09-26 |
2023-08-12 |
Not clear |
| Daniel J Drucke. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature clinical practice. Endocrinology & metabolism. vol 1. issue 1. 2006-09-15. PMID:16929363. |
glp-1 controls blood glucose through regulation of glucose-dependent insulin secretion, inhibition of glucagon secretion and gastric emptying, and reduction of food intake. |
2006-09-15 |
2023-08-12 |
human |
| Daniel J Drucke. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature clinical practice. Endocrinology & metabolism. vol 1. issue 1. 2006-09-15. PMID:16929363. |
dipeptidyl-peptidase-iv inhibitors, currently in phase iii clinical trials, stabilize the postprandial levels of glp-1 and gastric inhibitory polypeptide and lower blood glucose in diabetic patients via inhibition of glucagon secretion and enhancement of glucose-stimulated insulin secretion. |
2006-09-15 |
2023-08-12 |
human |
| Hiroshi Yasuda, Yuji Hayashi, Takahito Jomori, Fumio Takaiw. The correlation between expression and localization of a foreign gene product in rice endosperm. Plant & cell physiology. vol 47. issue 6. 2006-09-11. PMID:16614094. |
glucagon-like peptide 1 (glp-1) is a 30 amino acid peptide hormone involved in insulin stimulation that is dependent upon blood glucose levels. |
2006-09-11 |
2023-08-12 |
Not clear |
| Curtis Triplitt, Alison Wright, Elaine Chiquett. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy. vol 26. issue 3. 2006-09-01. PMID:16503716. |
in particular, the glucoregulatory actions of the incretin hormone glp-1 include enhancement of glucosedependent insulin secretion, suppression of inappropriately elevated glucagon secretion, slowing of gastric emptying, and reduction of food intake. |
2006-09-01 |
2023-08-12 |
Not clear |
| Curtis Triplitt, Alison Wright, Elaine Chiquett. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy. vol 26. issue 3. 2006-09-01. PMID:16503716. |
one is the use of agents that mimic the enhancement of glucose-dependent insulin secretion, and potentially other antihyperglycemic actions of incretins, and the other is the use of dipeptidyl peptidase-iv inhibitors, which reduce the inactivation of glp-1, increasing the concentration of endogenous glp-1. |
2006-09-01 |
2023-08-12 |
Not clear |
| Brian D Green, Kerry S Lavery, Nigel Irwin, Finbarr P M O'harte, Patrick Harriott, Brett Greer, Clifford J Bailey, Peter R Flat. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. The Journal of pharmacology and experimental therapeutics. vol 318. issue 2. 2006-08-31. PMID:16648370. |
acute intraperitoneal administration of (val8)glp-1 (6.25-25 nmol/kg) with glucose increased the insulin response and reduced the glycemic excursion in a dose-dependent manner. |
2006-08-31 |
2023-08-12 |
mouse |
| Brian D Green, Kerry S Lavery, Nigel Irwin, Finbarr P M O'harte, Patrick Harriott, Brett Greer, Clifford J Bailey, Peter R Flat. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. The Journal of pharmacology and experimental therapeutics. vol 318. issue 2. 2006-08-31. PMID:16648370. |
once-daily subcutaneous administration of (val8)glp-1 (25 nmol/kg) for 21 days reduced plasma glucose concentrations, increased plasma insulin, and reduced body weight more than native glp-1 without a significant change in daily food intake. |
2006-08-31 |
2023-08-12 |
mouse |
| Brian D Green, Kerry S Lavery, Nigel Irwin, Finbarr P M O'harte, Patrick Harriott, Brett Greer, Clifford J Bailey, Peter R Flat. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. The Journal of pharmacology and experimental therapeutics. vol 318. issue 2. 2006-08-31. PMID:16648370. |
furthermore, (val8)glp-1 improved glucose tolerance, reduced the glycemic excursion after feeding, increased the plasma insulin response to glucose and feeding, and improved insulin sensitivity. |
2006-08-31 |
2023-08-12 |
mouse |
| B Gallwit. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva endocrinologica. vol 31. issue 2. 2006-08-30. PMID:16682937. |
type 2 diabetes is characterized by an incretin defect: while gip does not stimulate insulin secretion, glp-1 action is still preserved under supraphysiological concentrations. |
2006-08-30 |
2023-08-12 |
Not clear |
| B Gallwit. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva endocrinologica. vol 31. issue 2. 2006-08-30. PMID:16682937. |
glp-1 stimulates insulin secretion only under hyperglycaemic conditions, therefore it does not cause hypoglycaemia. |
2006-08-30 |
2023-08-12 |
Not clear |
| B Gallwit. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva endocrinologica. vol 31. issue 2. 2006-08-30. PMID:16682937. |
the improvement of beta cell function can be indirectly observed from the increased insulin secretory capacity of humans receiving glp-1. |
2006-08-30 |
2023-08-12 |
Not clear |
| Juris J Meier, Michael A Nauc. Incretins and the development of type 2 diabetes. Current diabetes reports. vol 6. issue 3. 2006-08-25. PMID:16898571. |
the incretin hormones gastric inhibitory polypeptide (gip) and glucagon-like peptide 1 (glp-1) are released in response to nutrient ingestion and potentiate glucose-stimulated insulin secretion from pancreatic beta cells. |
2006-08-25 |
2023-08-12 |
Not clear |
| Li-Xin Li, Patrick E MacDonald, Diane S Ahn, Gavin Y Oudit, Peter H Backx, Patricia L Brubake. Role of phosphatidylinositol 3-kinasegamma in the beta-cell: interactions with glucagon-like peptide-1. Endocrinology. vol 147. issue 7. 2006-07-24. PMID:16574789. |
these studies reveal a new role for pi3-kgamma as a positive regulator of insulin secretion, and reinforce the importance of glp-1 for the maintenance of normal beta-cell function. |
2006-07-24 |
2023-08-12 |
mouse |